Answers are grounded in this paper and cite their sources.
Tafolecimab was safe and showed robust lipid-lowering efficacy in Chinese patients at high or very high cardiovascular risk with hypercholesterolemia. (A Study of IBI306 in Participants With Hypercholesterolemia; NCT04709536).
No takes yet. Share an insight, caveat, or question.
Qi et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: